NCT03333915View on ClinicalTrials.gov

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 21, 2016

Primary Completion Date

August 24, 2020

Study Completion Date

August 11, 2021

Conditions
Advanced High-grade Ovarian CancerTriple Negative Breast Cancer
Interventions
DRUG

Pamiparib

Pamiparib is provided as oral capsules

Trial Locations (6)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

200000

Fudan University Shanghai Cancer Center, Shanghai

310022

Zhejiang Cancer Hospital, Hangzhou

410013

Hunan Cancer Hospital, Changsha

450000

Henan Cancer Hospital, Zhengzhou

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03333915 - Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter